Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study

Table 2 Subgroup analyses of 3-year overall survival

Subgroups	Events/number	3-year OS, % (95% CI)	P-value*
pCR
No	1/14	92.9 (59.1, 99.0)	0.335
Yes	0/13	100.0 (100.0, 100.0)
Postoperative pathological node status
pN +	1/8	87.5 (38.7, 98.1)	0.123
pN0	0/19	100.0 (100.0, 100.0)
PD-L1 CPS
< 1	1/20	95.0 (69.5, 99.3)	0.584
≥ 1	0/6	100.0 (100.0, 100.0)
Baseline CRM status assessed by MRI
Positive	2/21	90.5 (67.0, 97.5)	0.349
Negative	0/9	100.0 (100.0, 100.0)
Baseline EMVI status
Positive	2/12	83.3 (48.2, 95.6)	0.077
Negative	0/18	100.0 (100.0, 100.0)

^*P-value was nominal, as determined by log-rank test. CI, confidence interval; CPS, combined positive score; CRM, circumferential resection margin; EMVI, extramural venous invasion, MRI, magnetic resonance imaging; OS, overall survival; pCR, pathological complete response; PD-L1, programmed cell death-ligand 1

ISSN: 1741-7015